GlaxoSmithKline news from FierceBiotech
NewsGSK, Valeant ink $820M epilepsy deal
Valeant Pharmaceuticals will pocket a $125 million upfront fee from GlaxoSmithKline in exchange for a collaboration deal on the epilepsy drug Read more...
Chemists laid off at GlaxoSmithKline
GlaxoSmithKline's June announcement that it was cutting 350 jobs worldwide is coming to fruition. Read more...
GSK, Genmab report strong ofatumumab data
So far, it looks like GlaxoSmithKline's $2.1 billion deal for HuMax-CD20 was money well spent. Inerim data from a Phase Read more...
GSK, Harvard ink stem cell research pact
In another instance of the industry teaming up with academia, GlaxoSmithKline and Harvard Stem Cell Institute (HSCI) announced that they have signed a five-year, $25 million pact to research and Read more...
GSK chief elaborates on biotech strategy
With profits sliding, GlaxoSmithKline CEO Andrew Witty used much of his second quarter review for analysts to amplify plans to radically alter its R&D work, abandoning its old focus on Read more...
Theravance wins $10M milestone on Phase II data
Mid-stage data from an experimental COPD therapy under development by GlaxoSmithKline researchers came in positive, and that will be worth a $10 million milestone payment for Theravance. Theravance Read more...
GSK inks $3.25B insomnia pact with Actelion
GlaxoSmithKline has partnered with Actelion in a whopping 3.3 billion Swiss franc pact ($3.25 billion) covering a new insomnia therapy now in late-stage studies. Actelion nabs 150 million francs Read more...
Glaxo to double China R&D
GlaxoSmithKline is making ambitious plans to expand its R&D operations in China. According to Glaxo's Carol Zhu, who runs the operation, the company will more than double the number of Read more...
GSK looks to gov. agencies for R&D advice
GlaxoSmithKline's newly appointed CEO Andrew Witty has seen the future of drug development, and government health care systems will play an even bigger role in it. In an interview with the Wall Read more...
GSK, Exelixis pact comes to a close
GlaxoSmithKline is ending its six-year-long collaboration with Exelixis in October. GSK has the right to select up to two Exelixis compounds for further development; it has already chosen Read more...
| Press ReleasesGlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND CAMBRIDGE, Mass., April 22 -- Read more... GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more... GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more... PRESS RELEASE: GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breas GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases Data on abstract 6076 embargoed until Sunday 16 December Read more... PRESS RELEASE: GlaxoSmithKline Receives FDA 'Complete Response' Letter; Cervical Cancer Vaccine Hit by Delay GlaxoSmithKline Receives FDA 'Complete Response' Letter; Cervical Cancer Vaccine Hit by Delay PHILADELPHIA, Dec. 17 -- GlaxoSmithKline announced today that it has received a complete response letter Read more... |
Get more GlaxoSmithKline coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets